News
GMT hires Jonny Maxwell
Jonny Maxwell, GMT
Robins joins SVG board
David Robins, SVG Capital
Catapult hires Lowe
Jonathan Lowe, Catapult Venture Managers
EdRip's fourth life sciences fund nears target
Edmond de Rothschild Investment Partners (EdRip) has so far raised €192m for its fourth life sciences fund, BioDiscovery 4, meaning the vehicle is close to reaching its target.
CMS Hasche Sigle hires Clifford Chance's Thomas Brunn
Thomas Brunn, CMS Hasche Sigle
Hellman & Friedman in Wood Mackenzie dividend recap
Hellman & Friedman has secured a dividend recap for UK-based consultancy Wood Mackenzie, according to reports.
German GPs cautious on venture
Kreditanstalt für Wiederaufbau (KfW) and BVK, the German private equity and venture capital association, have published a survey revealing decreased confidence in early-stage investments from local deal-doers in Q2.
Hengeler Mueller PE partner relocates to London
German law firm Hengeler Mueller has transferred one of its private equity partners, Steffen OppenlУЄnder, to its London office.
Azulis set to hit the road in 2014
French mid-cap GP Azulis Capital is planning to start a new fundraising effort in the first half of 2014. Managing partner Michel Rowan talks to Greg Gille about the upcoming vehicle and the firm’s evolution
GP churn boosts IRR
Further to initial findings announced in 2011, additional research by Capital Dynamics and London Business School’s Coller Institute of Private Equity has concluded that higher team turnover in buyout houses improves overall performance.
Christian Brønden joins Industriens Pension
Danish pension fund Industriens Pension has appointed Christian Raaby BrУИnden as director of private investments.
TEP seeks €100m for new fund
Time Equity Partners (TEP) has launched its second venture capital fund and is seeking to raise €100m, having already collected two thirds of its target, according to reports in the French press.
Lloyds appoints new acquisition finance director
Lloyds Bank Commercial Banking has hired Eric Jenkins as a director in its acquisition finance division.
Mark Owen steps down from NBGI
Mark Owen, co-founder of NBGI Private Equity, has announced his retirement from the firm.
SVG enjoys 23% NAV boost in H1
SVG Capital has reported a 23% uplift in net asset value (NAV) in its half-year results, with shares now trading at 480p.
Whitworths set for tertiary deal
Food company Whitworths looks set to fall into the hands of a third private equity owner as current backer European Capital seeks an exit.
Goldman Sachs appoints new head of EMEA financial sponsors group
Alasdair Warren, Goldman Sachs
Switzerland to increase start-up support via new fund-of-funds
The Swiss Private Equity & Corporate Finance Association (Seca) has teamed up with Swiss investment platform CTI Invest to set up a CHF 500m fund-of-funds to support local start-ups.
Kreos Capital leads round for GetTaxi
European GP Kreos Capital has led a $12m series-C funding round for GetTaxi, an enterprise and consumer taxi app, as the company launches its first US office.
Riverstone Holdings to float energy vehicle
Energy-focused private equity firm Riverstone Holdings is to float its latest energy vehicle in London, according to reports.
GSK launches $50m venture capital fund
GlaxoSmithKline (GSK) has launched a $50m strategic venture capital fund, Action Potential Venture Capital (APVC), to make investments in the biotech and bioelectric medicines industries.
3i-backed Element Materials secures financing from lenders
Element Materials Technology, a material testing and inspection firm backed by 3i, has secured additional financing from its bank lenders to boost its buy-and-build strategy.
FCA calls for AIFMD applications by January 2014
The FCA has advised firms managing alternative investment funds (AIFs) to submit applications by no later than 22 January 2014, ahead of the official 21 July 2014 deadline.
Ex-Premier Foods boss to advise KKR on Lucozade and Ribena bid
KKR is understood to have brought in Michael Clarke, the former CEO of Premier Foods, to advise on its ТЃ1.5bn bid for Lucozade and Ribena from GlaxoSmithKline (GSK).